Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
linaprazan glurate
- Development stage
- Phase 3
- Lead developer
- Cinclus Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Linaprazan glurate is an orally administered, small molecule prodrug of linaprazan, developed as a next-generation potassium-competitive acid blocker (P-CAB). It acts by competitively inhibiting the potassium ion activity of the gastric H+/K+-ATPase enzyme, resulting in rapid and sustained suppression of gastric acid secretion. Linaprazan glurate is designed for the treatment of erosive gastroesophageal reflux disease (eGERD), including healing and maintenance therapy, especially in patients with moderate to severe eGERD or those not adequately controlled by proton pump inhibitors. The drug has also been investigated for duodenal ulcer and Helicobacter pylori infection. Compared to earlier P-CABs, it offers a longer plasma half-life and improved pharmacokinetic profile, enabling effective 24-hour pH control with a favorable safety profile[1][3][5][7].
- Brand names
- Linaprazan Glurate
- Other names
- 1228559-81-63VG4D399DT
02
Targets
ATP4A (Potassium–transporting ATPase alpha chain 1)
Beyond the preview
Go deeper on linaprazan glurate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on linaprazan glurate.